Findings from a multi-center, international clinical trial reported by a Cleveland Clinic physician show that semaglutide reduced cardiovascular events by 20 percent in adults with overweight or obesity and established cardiovascular disease who don’t have diabetes. A. Michael Lincoff, MD, SELECT’s lead author and vice chair for research in Cleveland Clinic’s Department of Cardiovascular Medicine, provides an overview of the SELECT trial and findings.
More Episodes
The First Stopped Heart Surgery
2022-02-03
2022-02-03
Talking Tall Rounds®: Mitral Valve Disease
2021-12-23
2021-12-23
A Look at Echocardiography
2021-12-16
2021-12-16
Cardiac Sarcoidosis
2021-12-02
2021-12-02
Physiologic Pacing
2021-11-04
2021-11-04
Alcohol Septal Ablation
2021-10-21
2021-10-21
Sleep Apnea and Cardiovascular Disease
2021-10-07
2021-10-07
Talking Tall Rounds®: Inherited Arrhythmia's
2021-09-23
2021-09-23
Get this podcast on your
phone, FREE
